|
1
|
Ukawa S, Tamakoshi A, Yatsuya H, Yamagishi
K, Ando M and Iso H: JACC Study Group: Passive smoking and chronic
obstructive pulmonary disease mortality: Findings from the Japan
collaborative cohort study. Int J Public Health. 62:489–494. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeVries R, Kriebel D and Sama S: Outdoor
air pollution and COPD-related emergency department visits,
hospital admissions, and mortality: A meta-analysis. COPD.
14:113–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohno Y, Koyama H, Yoshikawa T, Matsumoto
K, Aoyama N, Onishi Y, Takenaka D, Matsumoto S, Nishimura Y and
Sugimura K: Comparison of capability of dynamic
O2-enhanced MRI and quantitative thin-section MDCT to
assess COPD in smokers. Eur J Radiol. 81:1068–1075. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diaz-Guzman E and Mannino DM: Epidemiology
and prevalence of chronic obstructive pulmonary disease. Clin Chest
Med. 35:7–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rabe KF, Hurd S, Anzueto A, Barnes PJ,
Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R,
van Weel C and Zielinski J: Global Initiative for Chronic
Obstructive Lung Disease: Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary
disease: GOLD executive summary. Am J Respir Crit Care Med.
176:532–555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vestbo J, Hurd SS, Agusti AG, Jones PW,
Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ,
Nishimura M, et al: Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease: GOLD
executive summary. Am J Respir Crit Care Med. 187:347–365. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta D, Agarwal R, Aggarwal AN, Maturu
VN, Dhooria S, Prasad KT, Sehgal IS, Yenge LB, Jindal A, Singh N,
Jindal SK, et al: for the COPD Guidelines Working Group: Guidelines
for diagnosis and management of chronic obstructive pulmonary
disease: Joint ICS/NCCP (I) recommendations. Lung India.
30:228–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bauer TT, Nilius G, Grüning W and Rasche
K: Diagnosis and therapy of COPD exacerbation. Med Klin Intensivmed
Notfmed. 107:172–178. 2012.(In German). PubMed/NCBI
|
|
9
|
Alía I, de la Cal MA, Esteban A, Abella A,
Ferrer R, Molina FJ, Torres A, Gordo F, Elizalde JJ, de Pablo R, et
al: Efficacy of corticosteroid therapy in patients with an acute
exacerbation of chronic obstructive pulmonary disease receiving
ventilatory support. Arch Intern Med. 171:1939–1946. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaude GS and Nadagouda S: Nebulized
corticosteroids in the management of acute exacerbation of COPD.
Lung India. 27:230–235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vestbo J, Hurd SS, Agustí AG, Jones PW,
Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ,
Nishimura M, et al: Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease: GOLD
executive summary. Am J Respir Crit Care Med. 187:347–365. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rutschmann OT, Cornuz J, Poletti PA,
Bridevaux PO, Hugli OW, Qanadli SD and Perrier A: Should pulmonary
embolism be suspected in exacerbation of chronic obstructive
pulmonary disease? Thorax. 62:121–125. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Araújo JP, Lourenço P, Azevedo A, Friões
F, Rocha-Gonçalves F, Ferreira A and Bettencourt P: Prognostic
value of high-sensitivity C-reactive protein in heart failure: A
systematic review. J Card Fail. 15:256–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lacoma A1, Prat C, Andreo F, Lores L,
Ruiz-Manzano J, Ausina V and Domínguez J: Value of procalcitonin,
C-reactive protein, and neopterin in exacerbations of chronic
obstructive pulmonary disease. Int J Chron Obstruct Pulmn Dis.
6:157–169. 2011.
|
|
15
|
Hur M, Moon HW, Yun YM, Kim KH, Kim HS and
Lee KM: Comparison of diagnostic utility between procalcitonin and
C-reactive protein for the patients with blood culture-positive
sepsis. Korean J Lab Med. 29:529–535. 2009.(In Korean). View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee JY, Hwang SJ, Shim JW, Jung HL, Park
MS, Woo HY and Shim JY: Clinical significance of serum
procalcitonin in patients with community-acquired lobar pneumonia.
Korean J Lab Med. 30:406–413. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Falsey AR, Becker KL, Swinburne AJ, Nylen
ES, Snider RH, Formica MA, Hennessey PA, Criddle MM, Peterson DR
and Walsh EE: Utility of serum procalcitonin values in patients
with acute exacerbations of chronic obstructive pulmonary disease:
a cautionary note. Int J Chron Obstruct Pulmon Dis. 7:127–135.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Albrich WC, Dusemund F, Bucher B, Meyer S,
Thomann R, Kühn F, Bassetti S, Sprenger M, Bachli E, Sigrist T, et
al: ProREAL Study Team: Effectiveness and safety of
procalcitonin-guided antibiotic therapy in lower respiratory tract
infections in ‘real life’: An international, multicenter poststudy
survey (ProREAL). Arch Intern Med. 172:715–722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siddiqui S, Hollins F, Saha S and
Brightling CE: Inflammatory cell microlocalisation and airway
dysfunction: Cause and effect? Eur Respir J. 30:1043–1056. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mikhak Z: Dose-response studies of
fluticasone propionate and budesonide: Classification based on
asthma severity. Allergy Asthma Proc. 27:402–411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alangari AA: Genomic and non-genomic
actions of glucocorticoids in asthma. Ann Thorac Med. 5:133–139.
2010. View Article : Google Scholar : PubMed/NCBI
|
